Clobetasol propionate ophthalmic nanoemulsion is in development for the treatment of post-operative pain or inflammation following cataract surgery. A cataract is a cloudy area in the lens, which can develop slowly and progress to general loss of transparency, which may lead to functional impairment and visual deterioration. Cataract surgery is the only effective treatment to improve or maintain vision, however, inflammation and pain are common difficulties following this treatment.
Clobetasol propionate ophthalmic nanoemulsion 0.05% is an oil in water solution that delivers the drug clobetasol propionate directly into the eye to treat inflammation and pain associated with cataract surgery. This technology promotes anti-inflammatory genes by binding to glucocorticoid receptors. If licensed, this treatment will offer an additional option for adults with postoperative pain and inflammation following cataract surgery.